ATE295421T1 - Verwendung eines replikationdefizienten adenoviralenvektors zur herstellung eines medikaments zur erhöhung der cd8+ t-zell- immunantwort gegen antigen - Google Patents

Verwendung eines replikationdefizienten adenoviralenvektors zur herstellung eines medikaments zur erhöhung der cd8+ t-zell- immunantwort gegen antigen

Info

Publication number
ATE295421T1
ATE295421T1 AT00960857T AT00960857T ATE295421T1 AT E295421 T1 ATE295421 T1 AT E295421T1 AT 00960857 T AT00960857 T AT 00960857T AT 00960857 T AT00960857 T AT 00960857T AT E295421 T1 ATE295421 T1 AT E295421T1
Authority
AT
Austria
Prior art keywords
antigen
replication
immune response
adenoviral vector
medication
Prior art date
Application number
AT00960857T
Other languages
German (de)
English (en)
Inventor
Joerg Schneider
Sarah Catherine Gilbert
Carolyn Mary Hannan
Adrian Vivian Sinton Hill
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10861351&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE295421(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Isis Innovation filed Critical Isis Innovation
Application granted granted Critical
Publication of ATE295421T1 publication Critical patent/ATE295421T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00960857T 1999-09-21 2000-09-20 Verwendung eines replikationdefizienten adenoviralenvektors zur herstellung eines medikaments zur erhöhung der cd8+ t-zell- immunantwort gegen antigen ATE295421T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9922361.2A GB9922361D0 (en) 1999-09-21 1999-09-21 Generating an immune response to an antigen
PCT/GB2000/003601 WO2001021201A2 (en) 1999-09-21 2000-09-20 Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen

Publications (1)

Publication Number Publication Date
ATE295421T1 true ATE295421T1 (de) 2005-05-15

Family

ID=10861351

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00960857T ATE295421T1 (de) 1999-09-21 2000-09-20 Verwendung eines replikationdefizienten adenoviralenvektors zur herstellung eines medikaments zur erhöhung der cd8+ t-zell- immunantwort gegen antigen

Country Status (12)

Country Link
EP (2) EP1612269A1 (enExample)
JP (1) JP2003509470A (enExample)
CN (1) CN1391609A (enExample)
AT (1) ATE295421T1 (enExample)
AU (1) AU762894B2 (enExample)
BR (1) BR0014138A (enExample)
CA (1) CA2384806A1 (enExample)
DE (1) DE60020136T2 (enExample)
DK (1) DK1214416T3 (enExample)
ES (1) ES2241653T3 (enExample)
GB (1) GB9922361D0 (enExample)
WO (1) WO2001021201A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9711957D0 (en) 1997-06-09 1997-08-06 Isis Innovation Methods and reagents for vaccination
EP1200622A4 (en) 1999-07-06 2004-12-22 Merck & Co Inc HIV VACCINE FROM AN ADENOVIRUS CARRYING THE GAG GENE
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
GB0118532D0 (en) * 2001-07-30 2001-09-19 Isis Innovation Materials and methods relating to improved vaccination strategies
WO2003097087A1 (en) * 2002-05-20 2003-11-27 Japan Science And Technology Agency Bcg vaccine and utilization thereof
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
EP1553983A2 (en) 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
CN100410382C (zh) * 2006-08-18 2008-08-13 上海交通大学医学院 一种可诱生细胞免疫应答的共表达载体和真核表达载体
AU2007322075B2 (en) * 2006-11-17 2013-07-25 Genetronics, Inc. Methods of enhancing immune response using electroporation-assisted vaccination and boosting
GB0706912D0 (en) * 2007-04-10 2007-05-16 Isis Innovation Novel viral vaccines
GB0706914D0 (en) 2007-04-10 2007-05-16 Isis Innovation Novel adenovirus vectors
JP5710254B2 (ja) * 2007-09-14 2015-04-30 アンスティテュ・パストゥールＩｎｓｔｉｔｕｔ Ｐａｓｔｅｕｒ 外来エピトープを含む組換え偽ウイルスの発現および分泌を可能とするポリヌクレオチド、それらの製造および使用
GB0823497D0 (en) * 2008-12-24 2009-01-28 Isis Innovation Immunogenic composition and use thereof
PT2912183T (pt) * 2012-10-28 2020-06-05 Bavarian Nordic As Promotor pr13.5 para respostas robustas de células t e anticorpos
KR20230166145A (ko) 2017-03-15 2023-12-06 옥스포드 바이오메디카(유케이) 리미티드 방법
MX2022004484A (es) * 2019-10-16 2022-07-19 Cancer Research Tech Ltd Vector para el tratamiento de cancer.
US20230310591A1 (en) 2021-12-07 2023-10-05 Vaccitech (Uk) Limited Vaccine Boost Methods and Compositions
WO2024218165A1 (en) 2023-04-17 2024-10-24 Barinthus Biotherapeutics (Uk) Limited Hpv viral vector vaccine

Also Published As

Publication number Publication date
EP1612269A1 (en) 2006-01-04
BR0014138A (pt) 2002-05-21
EP1214416A2 (en) 2002-06-19
AU762894B2 (en) 2003-07-10
CN1391609A (zh) 2003-01-15
WO2001021201A2 (en) 2001-03-29
EP1214416B1 (en) 2005-05-11
DE60020136T2 (de) 2006-02-23
DK1214416T3 (da) 2005-08-29
WO2001021201A3 (en) 2001-10-18
AU7302400A (en) 2001-04-24
JP2003509470A (ja) 2003-03-11
DE60020136D1 (de) 2005-06-16
ES2241653T3 (es) 2005-11-01
CA2384806A1 (en) 2001-03-29
GB9922361D0 (en) 1999-11-24

Similar Documents

Publication Publication Date Title
ATE295421T1 (de) Verwendung eines replikationdefizienten adenoviralenvektors zur herstellung eines medikaments zur erhöhung der cd8+ t-zell- immunantwort gegen antigen
Liu et al. Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation
DK0835133T3 (da) Rekombinant koppevirus-rabies-præparater og kombinationspræparater samt anvendelser deraf
BR9708387A (pt) Processo para vacinação de um mamìfero a um antìgeno selecionado, células patogênica e hospedeira, composição de vacina, ácido nucleico, e, opsonina engenheirada.
DE69434820D1 (de) Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis
DE69734882D1 (de) Dna immunisierung gegen chlamydia infektion
DE60141969D1 (de) Verwendung eines replikationdefizienten pockenvirusvektors zur erhöhung der cd4+ t-zell-immunantwort gegen antigen
DE69229476D1 (de) Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
ATE188740T1 (de) Viruspartikel mit veraendertem wirtspektrum
ATE347599T1 (de) Tuberkulose impfstoff
ATE212058T1 (de) Herstellung von einer immunantwort gegen prostat- spezifisches antigen (psa)
EP1217891A4 (en) THERAPEUTIC PROCEDURES AND COMPOSITIONS USING VIRUSES FROM THE RECOMBINANT FAMILY OF THE PARAMYXOVIRIDAE
WO2000053767A3 (en) Nucleic acid respiratory syncytial virus vaccines
DE60038620D1 (de) Dna immunisierung gegen chlamydia infektion
ATE105334T1 (de) Schimaerische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
NO983946D0 (no) Parapoksyviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner
EP1932915A3 (en) Materials and methods relating to improved vaccination strategies
WO2000030667A3 (en) Compositions and methods using lactadherin or variants thereof
ATE232903T1 (de) Impfstoff gegen geflügelkokzidose
ATE319833T1 (de) Impfstoffe zur erhöhung der immunantworten gegen herpes simplex virus
DK1272652T3 (da) Herpesvirus til immunmodulation
ATE201446T1 (de) Impfstoff gegen geflügelkokzidose
WO2004024756A3 (en) Orthopoxvirus antigens and use thereof
BRPI0209416A8 (pt) novos vetores de expressão e uso dos mesmos
WO2003075849A3 (en) Composition and method for enhancing immune response

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1214416

Country of ref document: EP

RZN Patent revoked